ALLG NHL26 A Phase 2 Study of patients treated for relapsed Follicular Lymphoma: with Revlimid (Registered Trademark) consolidation added to Rituximab maintenance therapy in those remaining Positron Emission Tomography (PET) positive

DOI number 10.58109/0219-pb05
Publisher Australasian Leukaemia and Lymphoma Group (ALLG)
Creator(s)

Australasian Leukaemia and Lymphoma Group (ALLG)

Judith Trotman (Concord Hospital)
Date Made Available 2023
Dataset Individual participant data (IPD) in aggregate form
Description of Dataset

Dataset includes:

  • Data for 37 patients with relapsed follicular lymphoma
  • PET response of all 37 registered patients at screening, 6 months post study treatment, and at diesease progression
  • QoL data for all patients up to 18 months of follow-up
  • 2 years of Rituximab and Lenolidomide treatmant data
  • Follow-up treatment data for all patients up to 18months
  • Comparsion of treatment arm data for coversion of PET+ to PET
  • Progression Free Survival and Overall survival data
Funding

Australasian Leukaemia and Lymphoma Group (ALLG)
Subject (ANZSRC Category)

Chemotherapy
ANZCTR Reference ACTRN12613000106730
Publication(s)
Dataset Access

Access can be requested via the Health Data Australia catalogue. Search for the ACTRN number in the catalogue to find datasets associated with this trial or email enquiries to info@allg.org.au
Memberships
Participate in a Trial
Memberships
Clinical Trials & Research
NHL24
NHL29